Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Price Expected to Rise, Oppenheimer Analyst Says

Pelthos Therapeutics (NYSEAMERICAN:PTHS) had its price objective boosted by equities researchers at Oppenheimer from $60.00 to $62.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price target would suggest a potential upside of 198.94% from the stock’s previous close.

A number of other equities analysts have also issued reports on the company. Piper Sandler began coverage on Pelthos Therapeutics in a research note on Friday, February 27th. They issued an “overweight” rating and a $48.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a research note on Thursday. Roth Mkm cut their price objective on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Finally, Zacks Research cut Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Pelthos Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Pelthos Therapeutics Stock Down 9.7%

NYSEAMERICAN:PTHS opened at $20.74 on Friday. Pelthos Therapeutics has a 12 month low of $9.00 and a 12 month high of $54.29. The business’s fifty day moving average is $23.28. The firm has a market capitalization of $67.20 million, a P/E ratio of -1.00 and a beta of 3.87.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ikarian Capital LLC lifted its position in Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after purchasing an additional 193,307 shares during the period. Boothbay Fund Management LLC grew its position in Pelthos Therapeutics by 279.8% during the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after purchasing an additional 59,435 shares during the period. J. Goldman & Co LP purchased a new position in shares of Pelthos Therapeutics during the 4th quarter valued at about $2,418,000. Cantor Fitzgerald L. P. purchased a new position in shares of Pelthos Therapeutics during the 4th quarter valued at about $1,085,000. Finally, Diadema Partners LP lifted its holdings in shares of Pelthos Therapeutics by 138.1% in the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after buying an additional 14,502 shares during the period. 77.96% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Pelthos Therapeutics

Here are the key news stories impacting Pelthos Therapeutics this week:

• Positive Sentiment: Oppenheimer raised its price target to $62 and kept an “outperform” rating, signaling continued institutional conviction in multi-year upside. Article Title
• Positive Sentiment: HC Wainwright increased long-term EPS forecasts materially for FY2028–FY2030 (FY2028 to $10.86, FY2029 to $15.42, FY2030 to $18.79), implying analysts expect the company’s pipeline or commercialization prospects to deliver significant profit expansion several years out. Article Title
• Neutral Sentiment: HC Wainwright reiterated a “Buy” rating with a $60 target — the firm remains constructive, but the rating alone is not offsetting concerns about near-term profitability revisions. Article Title
• Negative Sentiment: HC Wainwright sharply lowered near-term EPS estimates for 2026 across multiple quarters (Q1-Q4 2026) and cut FY2026 from about ($6.31) to ($14.39) — this large downgrade increases short-term execution and funding risk and is the primary likely catalyst for the stock’s decline today. Article Title

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).